A leading provider of
innovative DNA Screening solutions
cMYC Breakapart LPH010
Translocations involving the cMYC oncogene are similar in B-ALL as those in Burkitt's Lymphoma. In each case, this results in deregulation of cMYC, increased transcription and neoplastic growth. Patients with cMYC rearrangements were originally thought to have poor prognoses but they do respond well to intensive chemotherapy affording them an increased survival rate. This shows that cytogenetic confirmation of the rearrangement is necessary to manage the patient effectively.
cMYC Breakapart Probe
Cat. No. LPH 010-S (5 tests)
Cat. No. LPH 010 (10 tests)
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK